CL2016000251A1 - Anti-activin antibodies and uses thereof - Google Patents

Anti-activin antibodies and uses thereof

Info

Publication number
CL2016000251A1
CL2016000251A1 CL2016000251A CL2016000251A CL2016000251A1 CL 2016000251 A1 CL2016000251 A1 CL 2016000251A1 CL 2016000251 A CL2016000251 A CL 2016000251A CL 2016000251 A CL2016000251 A CL 2016000251A CL 2016000251 A1 CL2016000251 A1 CL 2016000251A1
Authority
CL
Chile
Prior art keywords
activin antibodies
activin
antibodies
Prior art date
Application number
CL2016000251A
Other languages
Spanish (es)
Inventor
Jesper Gromada
Esther Latres
Andrew J Murphy
George D Yancopoulos
Lori C Morton
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2016000251A1 publication Critical patent/CL2016000251A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
CL2016000251A 2013-07-30 2016-01-29 Anti-activin antibodies and uses thereof CL2016000251A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361859926P 2013-07-30 2013-07-30
US201361864036P 2013-08-09 2013-08-09
US201361911834P 2013-12-04 2013-12-04
US201361913885P 2013-12-09 2013-12-09

Publications (1)

Publication Number Publication Date
CL2016000251A1 true CL2016000251A1 (en) 2017-07-14

Family

ID=52427866

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000251A CL2016000251A1 (en) 2013-07-30 2016-01-29 Anti-activin antibodies and uses thereof

Country Status (28)

Country Link
US (4) US9718881B2 (en)
EP (4) EP3730151A1 (en)
JP (5) JP6581085B2 (en)
KR (2) KR102315694B1 (en)
CN (2) CN113845594A (en)
AU (2) AU2014296243B2 (en)
BR (1) BR112016002164B1 (en)
CA (1) CA2920071C (en)
CL (1) CL2016000251A1 (en)
CY (1) CY1123788T1 (en)
DK (1) DK3027209T3 (en)
EA (1) EA037926B1 (en)
ES (1) ES2827673T3 (en)
HK (1) HK1225322A1 (en)
HR (1) HRP20201729T1 (en)
HU (1) HUE052518T2 (en)
IL (2) IL243822B (en)
LT (1) LT3027209T (en)
MX (2) MX2020001201A (en)
PH (1) PH12016500182A1 (en)
PT (1) PT3027209T (en)
RS (1) RS61124B1 (en)
SG (1) SG11201600731WA (en)
SI (1) SI3027209T1 (en)
TW (2) TW201920262A (en)
UY (1) UY35682A (en)
WO (1) WO2015017576A1 (en)
ZA (1) ZA201601294B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160137665A (en) 2005-11-23 2016-11-30 악셀레론 파마 인코포레이티드 Activin-actrπa antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
AU2008211007B2 (en) 2007-02-01 2013-09-19 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for treating or preventing breast cancer
TW202021980A (en) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 Variants derived from actriib and uses therefor
CA3039330C (en) 2007-02-09 2021-11-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN107412734A (en) 2007-09-18 2017-12-01 阿塞勒隆制药公司 Activin A CTRIIA antagonists and the purposes for reducing or suppressing FSH secretions
JP5922928B2 (en) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド Use of GDF traps to increase red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010263182B2 (en) 2009-06-12 2016-05-12 Acceleron Pharma Inc. Truncated ActRIIB-Fc fusion proteins
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
ES2663946T3 (en) 2011-11-14 2018-04-17 Regeneron Pharmaceuticals, Inc. Compositions and methods to increase muscle mass and strength by specifically antagonizing GDF8 and / or Activin A
ES2884095T3 (en) 2012-11-02 2021-12-10 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
TW201920262A (en) 2013-07-30 2019-06-01 美商再生元醫藥公司 Anti-activin A antibodies and uses thereof
BR122023023170A2 (en) 2014-06-13 2024-02-20 Acceleron Pharma Inc. USE OF AN ACTRII ANTAGONIST IN THE TREATMENT OR PREVENTION OF SKIN ULCERS ASSOCIATED WITH BETA-THALASSEMIA
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EA039118B1 (en) * 2015-04-01 2021-12-07 Ридженерон Фармасьютикалз, Инк. Method for treating fibrodysplasia ossificans progressiva
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
EP3288976B1 (en) 2015-04-29 2020-04-08 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
TWI824372B (en) * 2015-10-12 2023-12-01 美商再生元醫藥公司 Antigen-binding proteins that activate the leptin receptor
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018067740A1 (en) * 2016-10-05 2018-04-12 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
WO2018075378A1 (en) * 2016-10-17 2018-04-26 Vanderbilt University Human respiratory syncytial virus antibodies and methods of use therefor
CN110430890A (en) * 2016-11-10 2019-11-08 科乐斯疗法公司 Activin receptor IIA type variant and its application method
DE102018103302A1 (en) * 2018-02-14 2019-08-14 Noonee Ag Portable sitting position help device
CN111787981A (en) * 2018-03-01 2020-10-16 瑞泽恩制药公司 Method of altering body composition
WO2019241350A1 (en) 2018-06-13 2019-12-19 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
CN113195532A (en) * 2018-12-18 2021-07-30 瑞泽恩制药公司 Compositions and methods for increasing body weight and lean muscle mass using antagonists against leptin receptor, GDF8, and activin A
EP3976630A4 (en) * 2019-05-30 2024-03-20 Acceleron Pharma Inc Actrii-binding proteins and uses thereof
KR20220139886A (en) 2020-01-08 2022-10-17 리제너론 파아마슈티컬스, 인크. Treatment of Progressive Osteogenic Fibrodysplasia
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
WO2021163170A1 (en) 2020-02-11 2021-08-19 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and uses thereof
KR20230026407A (en) 2020-06-18 2023-02-24 리제너론 파아마슈티컬스, 인크. Activin A antibody formulations and methods of use thereof
JP2023539107A (en) * 2020-08-20 2023-09-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods for preventing and treating cardiac dysfunction and COVID-19 using activin A antagonists
WO2023022968A2 (en) * 2021-08-16 2023-02-23 Acceleron Pharma Inc. Compositions and methods for treating renal diseases or conditions
WO2023069421A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023154672A2 (en) * 2022-02-14 2023-08-17 Ohio University Methods for regulating muscle performance using fat specific protein 27 (fsp27) compositions
TWI819587B (en) * 2022-04-29 2023-10-21 洪慧妤 Composition for prevention of cancer-induced sarcopenia and use thereof for manufacturing food for prevention of cancer-induced sarcopenia
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
DE69432815T2 (en) 1993-03-19 2003-12-11 Univ Johns Hopkins Med GROWTH FACTOR-8
JP4544742B2 (en) 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Treatment of diabetes by inhibition of GDF-8
MXPA01013232A (en) 1999-07-20 2005-05-24 Pharmexa As Method for down-regulating gdf-8 activity.
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AR047392A1 (en) 2002-10-22 2006-01-18 Wyeth Corp NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
BRPI0418317A (en) 2003-12-31 2007-05-02 Schering Plough Ltd neutralization epitope-based growth enhancement vaccine
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
ES2384176T3 (en) 2004-03-23 2012-07-02 Eli Lilly & Company Anti-myostatin antibodies
JP5848861B2 (en) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Human monoclonal antibody against CD20
BRPI0514253A (en) 2004-08-12 2008-06-03 Wyeth Corp combination therapy for diabetes, obesity and cardiovascular disease using compositions containing gdf-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer Antibodies to myostatin
ES2534760T3 (en) 2005-08-19 2015-04-28 Wyeth Llc Antagonist antibodies against GDF-8 and their uses in the treatment of ALS and other disorders associated with GDF-8
KR101135220B1 (en) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CN101370511B (en) * 2005-11-23 2015-07-01 阿塞勒隆制药公司 Activin-ActRlla antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP1968621A2 (en) 2005-12-06 2008-09-17 Amgen Inc. Uses of myostatin antagonists
MX2008014804A (en) 2006-06-02 2009-01-27 Regeneron Pharma High affinity antibodies to human il-6 receptor.
PL2066695T3 (en) 2006-09-05 2013-08-30 Lilly Co Eli Anti-myostatin antibodies
CL2007002567A1 (en) * 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
PE20090982A1 (en) 2007-11-05 2009-08-13 Novartis Ag PIPERIDINE DERIVATIVES AS CHOLESTERYL-ESTER TRANSFER PROTEIN (CETP) INHIBITORS
JP5922928B2 (en) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド Use of GDF traps to increase red blood cell levels
PE20120206A1 (en) * 2008-11-26 2012-03-09 Amgen Inc ACTIVIN IIB RECEPTOR POLYPEPTIDE VARIANTS
UY32341A (en) 2008-12-19 2010-07-30 Glaxo Group Ltd NEW ANTIGEN UNION PROTEINS
JP5766179B2 (en) 2009-04-27 2015-08-19 ノバルティス アーゲー Compositions and methods for increasing muscle growth
AU2010265933B2 (en) 2009-06-26 2015-05-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
ES2663946T3 (en) * 2011-11-14 2018-04-17 Regeneron Pharmaceuticals, Inc. Compositions and methods to increase muscle mass and strength by specifically antagonizing GDF8 and / or Activin A
GR1007832B (en) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Activin neutralisers and uses thereof for treatment of diseases associated with aberrant "host defence response" activation
JP6433889B2 (en) 2012-06-15 2018-12-05 ファイザー・インク Improved antagonistic antibodies against GDF-8 and uses thereof
MX2015009901A (en) 2013-02-01 2016-04-06 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject.
TW201920262A (en) 2013-07-30 2019-06-01 美商再生元醫藥公司 Anti-activin A antibodies and uses thereof
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
CN111787981A (en) * 2018-03-01 2020-10-16 瑞泽恩制药公司 Method of altering body composition

Also Published As

Publication number Publication date
KR102315694B1 (en) 2021-10-21
AU2020200892A1 (en) 2020-03-05
CA2920071A1 (en) 2015-02-05
JP7440464B2 (en) 2024-02-28
US10526403B2 (en) 2020-01-07
JP6581085B2 (en) 2019-09-25
NZ754959A (en) 2022-03-25
HRP20201729T1 (en) 2020-12-25
ZA201601294B (en) 2017-05-31
JP6923602B2 (en) 2021-08-25
JP2016528232A (en) 2016-09-15
EA201690243A1 (en) 2016-06-30
JP2022130593A (en) 2022-09-06
EP3027209A1 (en) 2016-06-08
DK3027209T3 (en) 2020-11-02
MX371498B (en) 2020-01-31
KR20160030581A (en) 2016-03-18
WO2015017576A1 (en) 2015-02-05
PH12016500182A1 (en) 2016-04-25
HUE052518T2 (en) 2021-05-28
IL243822A0 (en) 2016-04-21
CN105592858B (en) 2021-10-01
EP4059520A1 (en) 2022-09-21
KR20210129253A (en) 2021-10-27
TWI655207B (en) 2019-04-01
US20150037339A1 (en) 2015-02-05
JP2021176887A (en) 2021-11-11
US20180155416A1 (en) 2018-06-07
BR112016002164B1 (en) 2023-12-19
CY1123788T1 (en) 2022-03-24
PT3027209T (en) 2020-10-22
US9718881B2 (en) 2017-08-01
HK1225322A1 (en) 2017-09-08
TW201602133A (en) 2016-01-16
AU2014296243B2 (en) 2019-11-21
SI3027209T1 (en) 2020-11-30
JP2020011965A (en) 2020-01-23
MX2016001394A (en) 2016-08-03
SG11201600731WA (en) 2016-02-26
EP3730151A1 (en) 2020-10-28
CA2920071C (en) 2023-05-23
NZ716854A (en) 2022-03-25
MX2020001201A (en) 2021-01-28
EP3027209B1 (en) 2020-09-02
LT3027209T (en) 2020-12-28
RS61124B1 (en) 2020-12-31
EP4062937A1 (en) 2022-09-28
BR112016002164A2 (en) 2017-09-12
IL270218B (en) 2021-01-31
ES2827673T3 (en) 2021-05-24
AU2014296243A1 (en) 2016-03-03
EA037926B1 (en) 2021-06-08
US20230312699A1 (en) 2023-10-05
KR102440044B1 (en) 2022-09-06
US20210163583A1 (en) 2021-06-03
IL243822B (en) 2019-11-28
TW201920262A (en) 2019-06-01
JP2022160619A (en) 2022-10-19
CN113845594A (en) 2021-12-28
AU2020200892B2 (en) 2022-03-31
CN105592858A (en) 2016-05-18
UY35682A (en) 2015-02-27

Similar Documents

Publication Publication Date Title
CL2016000251A1 (en) Anti-activin antibodies and uses thereof
CL2016002252A1 (en) Anti-egfrviii antibodies and uses thereof
CL2015001924A1 (en) Anti-pdgfr-beta antibodies and related uses.
CL2016001241A1 (en) New pesticide compounds and uses
CL2016000981A1 (en) Strigolactone formulations and their uses
DK3336106T3 (en) ANTI-FCRH5 ANTIBODIES
DK3049441T3 (en) Anti-PDL1 antibody formulations
DK2970460T3 (en) Anti-IL-33 Antibodies and Uses thereof
CO6821892A2 (en) Anti-angptl3 antibodies and uses thereof
CL2016000777A1 (en) Cancer biomarkers and their uses
DK3708583T3 (en) NON-FUCOSYLED ANTI-FGFR2IIIB ANTIBODIES
DK3003039T3 (en) METHYL / FLUOR-PYRIDINYL-METOXY-SUBSTITUTED PYRIDINON-PYRIDINYL-COMPOUNDS AND FLUOR-PYRIMIDINYL-METOXY-SUBSTITUTED PYRIDINON-PYRIDINYL-CONNECTIONS
BR112016011147A2 (en) autoinjector
DK3071675T3 (en) COMBINED ENERGY
DK3068800T3 (en) FcRn-specific antibodies
ES2717446T3 (en) Peptides derived from ERK and uses thereof
DK3065774T3 (en) Anti-CCL17 antibodies
CL2014000649S1 (en) Umbrella
TH1501000327B (en) Absorbent
TH144599B (en) umbrella
UA26239S (en) STOPPER
TH1501000527B (en) Stopper
UA25504S (en) STOPPER
SM201300005S (en) Pendants
UA25141S (en) STOPPER